<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161316</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-09-04</org_study_id>
    <secondary_id>2009-017194-38</secondary_id>
    <nct_id>NCT01161316</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours</brief_title>
  <acronym>MACRO-2</acronym>
  <official_title>Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-line Treatment in Patients With Metastatic Colorectal Cancer (mCRC) and Wild-type KRAS Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the combination of&#xD;
      mFOLFOX-6 plus cetuximab for 8 cycles followed by mFOLFOX-6 plus cetuximab or single agent&#xD;
      (s/a) cetuximab as maintenance therapy in patients (pts) with metastatic colorectal cancer&#xD;
      (mCRC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2010-2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of objective responses</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease's resectability (R0)</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate hypomagnesaemia as a predictive factor in the treatment's efficacy</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFOX-6 + cetuximab until disease progression or early withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX-6 + cetuximab until disease progression or early withdrawal.</intervention_name>
    <description>Treatment regimen:&#xD;
mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours&#xD;
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.</intervention_name>
    <description>Treatment regimen.&#xD;
mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours&#xD;
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patients of an age ≥ 18 years and &lt; 71&#xD;
&#xD;
          -  Patients with an ECOG performance status ≤ 2&#xD;
&#xD;
          -  Confirmed histological diagnosis of colorectal carcinoma with metastatic disease and&#xD;
             wild-type KRAS.&#xD;
&#xD;
          -  Presence of at least one target lesion that is measurable one-dimensionally (not&#xD;
             located in an irradiated region).&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks.&#xD;
&#xD;
          -  First evidence of chemotherapy-naïve metastatic disease. Adjuvant chemotherapy is&#xD;
             allowed if it has been more than 6 months since the treatment was finished and there&#xD;
             have been no signs of disease progression, neither during treatment nor during the 6&#xD;
             months following its completion.&#xD;
&#xD;
          -  Adequate medullar reserve:&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 109/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
          -  Haemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Adequate renal function: Creatinine clearance &gt; 30 mL/min, calculated using the&#xD;
             Cockroff-Gault formula, or a serum creatinine &lt; 2 mg/dL or 177 umol/L&#xD;
&#xD;
          -  An adequate liver function: ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 x ULN (≤ 5 x ULN if&#xD;
             there are liver metastases). Total bilirubin &lt; 1.5 x ULN. Alkaline phosphatase ≤ 2.5 x&#xD;
             ULN ( ≤ 5 x ULN in the case of liver metastases or ≤ 10 x ULN in the case of bone&#xD;
             metastases)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To have received prior systemic treatment for the metastatic disease&#xD;
&#xD;
          -  Diagnosis or suspicion of brain or leptomeningeal metastases&#xD;
&#xD;
          -  Major surgery or radiotherapy (except for antalgic surgery that does not include&#xD;
             measurable target lesions) during the 4 weeks prior to inclusion in the study.&#xD;
&#xD;
          -  Previous administration of monoclonal antibodies, agents inhibiting EGFR signal&#xD;
             transduction or EGFR-targeted treatment.&#xD;
&#xD;
          -  Participation in another clinical trial with drugs within the previous 30 days.&#xD;
&#xD;
          -  Neoplasm in the 2 years prior to entering the study, except for non-melanoma skin&#xD;
             carcinoma or in situ cervix carcinoma.&#xD;
&#xD;
          -  Evidence of previous acute hypersensitivity reaction of any degree to any of the&#xD;
             treatment's components.&#xD;
&#xD;
          -  Clinically relevant peripheral neuropathy.&#xD;
&#xD;
          -  Signs and symptoms, at the moment of entering the study, of acute or subacute bowel&#xD;
             obstruction.&#xD;
&#xD;
          -  A history of an acute episode of ischemic heart disease (angina or acute myocardial&#xD;
             infarction) within the previous 12 months or an elevated risk of heart failure&#xD;
             decompensation or uncontrolled arrhythmia.&#xD;
&#xD;
          -  Serious active infection, including active tuberculosis and HIV diagnosis.&#xD;
&#xD;
          -  Chronic immunological or hormonal treatment, except for hormone replacement treatment&#xD;
             at physiological doses.&#xD;
&#xD;
          -  Known drug or alcohol abuse.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. Premenopausal women must have a negative pregnancy test in&#xD;
             urine or blood before entering the trial. Patients and their partners must take&#xD;
             contraceptive measures (hormonal, barrier, or abstinence) if the possibility of&#xD;
             conception exists, during the study and for 3 months after the end of the treatment&#xD;
             thereof.&#xD;
&#xD;
          -  Any geographical or social circumstance or any medical or psychological alteration&#xD;
             that, in the investigator's opinion, will not allow the patient to conclude the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Aranda</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina Sofia. Córdoba. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Díaz-Rubio</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico San Carlos. Madrid. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>wild-type KRAS tumours</keyword>
  <keyword>cetuximab</keyword>
  <keyword>mFOLFOX-6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

